These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 31737426)

  • 21. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.
    Xie Y; Xiao D; Li D; Peng M; Peng W; Duan H; Yang X
    Front Oncol; 2024; 14():1441222. PubMed ID: 39156700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
    Han Y; Chen MK; Wang HL; Hsu JL; Li CW; Chu YY; Liu CX; Nie L; Chan LC; Yam C; Wang SC; He GJ; Hortobagyi GN; Tan XD; Hung MC
    Am J Cancer Res; 2019; 9(3):608-618. PubMed ID: 30949414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    Nizialek E; Antonarakis ES
    Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
    Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
    Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Moutafi M; Economopoulou P; Rimm D; Psyrri A
    Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 27. BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.
    Collet L; Hanvic B; Turinetto M; Treilleux I; Chopin N; Le Saux O; Ray-Coquard I
    Front Oncol; 2024; 14():1354427. PubMed ID: 38544832
    [No Abstract]   [Full Text] [Related]  

  • 28. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
    Rose M; Burgess JT; O'Byrne K; Richard DJ; Bolderson E
    Front Cell Dev Biol; 2020; 8():564601. PubMed ID: 33015058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
    Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
    Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
    Wu Z; Cui P; Tao H; Zhang S; Ma J; Liu Z; Wang J; Qian Y; Chen S; Huang Z; Zheng X; Huang D; Hu Y
    Clin Med Insights Oncol; 2021; 15():1179554921996288. PubMed ID: 33737855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
    Peyraud F; Italiano A
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
    Csizmar CM; Saliba AN; Swisher EM; Kaufmann SH
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.
    Catalano M; Francesco Iannone L; Cosso F; Generali D; Mini E; Roviello G
    Expert Opin Ther Targets; 2022 Nov; 26(11):923-936. PubMed ID: 36519314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harnessing DNA Double-Strand Break Repair for Cancer Treatment.
    Trenner A; Sartori AA
    Front Oncol; 2019; 9():1388. PubMed ID: 31921645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
    Morgan RD; Clamp AR; Evans DGR; Edmondson RJ; Jayson GC
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):647-658. PubMed ID: 29464354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells.
    Li H; Chatla S; Liu X; Vekariya U; Kim D; Walt M; Lian Z; Morton G; Feng Z; Yang D; Liu H; Reed K; Childers W; Yu X; Madzo J; Chitrala KN; Skorski T; Huang J
    Res Sq; 2023 Apr; ():. PubMed ID: 37066268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
    Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
    Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
    Wilson A; Menon V; Khan Z; Alam A; Litovchick L; Yakovlev V
    Redox Biol; 2019 Jun; 24():101169. PubMed ID: 30889466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.